HUP0300576A2 - Érkárosító hatású, osztott dózisú gyógyászati készítmény - Google Patents

Érkárosító hatású, osztott dózisú gyógyászati készítmény

Info

Publication number
HUP0300576A2
HUP0300576A2 HU0300576A HUP0300576A HUP0300576A2 HU P0300576 A2 HUP0300576 A2 HU P0300576A2 HU 0300576 A HU0300576 A HU 0300576A HU P0300576 A HUP0300576 A HU P0300576A HU P0300576 A2 HUP0300576 A2 HU P0300576A2
Authority
HU
Hungary
Prior art keywords
divided dose
vascular damaging
damaging activity
dose therapies
medicinal preparations
Prior art date
Application number
HU0300576A
Other languages
English (en)
Inventor
Peter David Davis
Original Assignee
Angiogene Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0007740A external-priority patent/GB0007740D0/en
Priority claimed from GB0013928A external-priority patent/GB0013928D0/en
Priority claimed from GB0014904A external-priority patent/GB0014904D0/en
Application filed by Angiogene Pharmaceuticals Ltd. filed Critical Angiogene Pharmaceuticals Ltd.
Publication of HUP0300576A2 publication Critical patent/HUP0300576A2/hu
Publication of HUP0300576A3 publication Critical patent/HUP0300576A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány olyan gyógyászati készítményekre, közelebbrőlgyógyszerkészítményekre vagy gyógyszerkészletekre vonatkozik, amelyekegy érkárosító szert vagy gyógyászatilag alkalmazható sójáttartalmazzák egy teljes napi dózist kitevő két vagy több részdózisraelosztott formában. A részdózisok célszerűen dózisegységek formájóbanvannak kiszerelve. A találmány szerinti gyógyászati készítményekérkárosító szerként előnyösen (I) képletű vegyületet (ZD-6126-ot)tartalmaznak. Ó
HU0300576A 2000-03-31 2001-03-27 Divided dose therapies with vascular damaging activity HUP0300576A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0007740A GB0007740D0 (en) 2000-03-31 2000-03-31 Combination therapy
GB0013928A GB0013928D0 (en) 2000-06-08 2000-06-08 Methods of treatment
GB0014904A GB0014904D0 (en) 2000-06-20 2000-06-20 Methods of treatment
PCT/GB2001/001329 WO2001074369A1 (en) 2000-03-31 2001-03-27 Divided dose therapies with vascular damaging activity

Publications (2)

Publication Number Publication Date
HUP0300576A2 true HUP0300576A2 (hu) 2003-07-28
HUP0300576A3 HUP0300576A3 (en) 2005-02-28

Family

ID=27255635

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300576A HUP0300576A3 (en) 2000-03-31 2001-03-27 Divided dose therapies with vascular damaging activity

Country Status (23)

Country Link
US (1) US20030055024A1 (hu)
EP (1) EP1272200B1 (hu)
JP (1) JP2003528921A (hu)
KR (1) KR20020084267A (hu)
CN (1) CN1422157A (hu)
AT (1) ATE298240T1 (hu)
AU (2) AU4258601A (hu)
BR (1) BR0109671A (hu)
CA (1) CA2402078A1 (hu)
CZ (1) CZ20023231A3 (hu)
DE (1) DE60111622T2 (hu)
EE (1) EE200200549A (hu)
ES (1) ES2243466T3 (hu)
HU (1) HUP0300576A3 (hu)
IL (1) IL151627A0 (hu)
IS (1) IS6555A (hu)
MX (1) MXPA02009603A (hu)
NO (1) NO20024683L (hu)
NZ (1) NZ534190A (hu)
PL (1) PL357282A1 (hu)
PT (1) PT1272200E (hu)
SK (1) SK13902002A3 (hu)
WO (1) WO2001074369A1 (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200200565A (et) * 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
US20040067255A1 (en) * 2002-10-07 2004-04-08 Chaplin David J. Method of administering split doses of a vascular targeting agent
GB0223379D0 (en) * 2002-10-09 2002-11-13 Angiogene Pharm Ltd Combination therapy
FR2848212B1 (fr) * 2002-12-06 2006-10-27 Aventis Pharma Sa Derives de la colchicine, procede de preparation, produits obtenus par ce procede et utilisation
EP1658084A2 (en) * 2003-06-18 2006-05-24 Angiogene Pharmaceuticals Ltd Compositions comprising zd6126 together with 5-fu, cpt-11 or 5-fu and cpt-11 having vascular damaging activity for treating e.g. colorectal cancer
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0316123D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO86439B (ro) * 1982-01-15 1985-03-31 Eli Lilly And Company Procedeu pentru prepararea unor derivati de acid ascorbic
US4996237A (en) * 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
AU6605690A (en) * 1989-10-27 1991-05-31 Du Pont Merck Pharmaceutical Company, The Monoclonal antibodies to basic fibroblast growth factor that inhibit its biological activity
ES2064101T3 (es) * 1990-04-02 1995-01-16 Pfizer Compuestos de acido bencilfosfonico inhibidores de la quinasa de tirosina.
US6194439B1 (en) * 1991-05-29 2001-02-27 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
GB9714249D0 (en) * 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
JPH11228594A (ja) * 1998-02-16 1999-08-24 Meiji Milk Prod Co Ltd 新規プロゲステロン化合物
ES2265948T3 (es) * 1999-06-14 2007-03-01 Cancer Research Technology Limited Terapia para el cancer.
US20040067255A1 (en) * 2002-10-07 2004-04-08 Chaplin David J. Method of administering split doses of a vascular targeting agent

Also Published As

Publication number Publication date
BR0109671A (pt) 2003-02-04
CA2402078A1 (en) 2001-10-11
AU2001242586B2 (en) 2004-12-16
WO2001074369A1 (en) 2001-10-11
PT1272200E (pt) 2005-09-30
SK13902002A3 (sk) 2003-05-02
NO20024683D0 (no) 2002-09-30
ES2243466T3 (es) 2005-12-01
NZ534190A (en) 2007-05-31
AU4258601A (en) 2001-10-15
DE60111622T2 (de) 2006-05-18
US20030055024A1 (en) 2003-03-20
EE200200549A (et) 2004-02-16
IS6555A (is) 2002-10-18
IL151627A0 (en) 2003-04-10
PL357282A1 (en) 2004-07-26
CZ20023231A3 (cs) 2003-01-15
JP2003528921A (ja) 2003-09-30
CN1422157A (zh) 2003-06-04
DE60111622D1 (de) 2005-07-28
MXPA02009603A (es) 2004-05-14
ATE298240T1 (de) 2005-07-15
EP1272200B1 (en) 2005-06-22
EP1272200A1 (en) 2003-01-08
HUP0300576A3 (en) 2005-02-28
NO20024683L (no) 2002-10-15
KR20020084267A (ko) 2002-11-04

Similar Documents

Publication Publication Date Title
EE05074B1 (et) Sulfoonamiid- ja sulfamiidasendatud imidasokinoliinid, nende kasutamine raviks ja neid sisaldavad farmatseutilised preparaadid
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
TW200503685A (en) A pharmaceutical composition for inhibiting coronavirus
SE0001899D0 (sv) New compounds
MX2007006212A (es) Medicamento oral para liberacion modificada de al menos un principio activo bajo forma multimicrocapsular.
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
BR0015188A (pt) Composições farmacêuticas
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
MA30966B1 (fr) Combinaison d'inhibiteurs de iap et d'inhibiteurs de flt3
NO20055631L (no) Doseringsform inneholdende pantoprazol som aktiv ingrediens
IL151628A0 (en) Combination therapies with vascular damaging activity
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
SE9802208D0 (sv) Novel compounds
ES2180933T3 (es) Inhibidor de la serina-proteasa.
HUP0004282A2 (hu) 2-Halogén-6-0-szubsztituált ketolidszármazékok
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
HUP0300576A2 (hu) Érkárosító hatású, osztott dózisú gyógyászati készítmény
TNSN07203A1 (en) Pharmaceutical compositions for the treatment of cellulite
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
ATE253359T1 (de) Antithrombotische mittel
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
DK1140115T3 (da) Phospholipidkomplekser af proanthocyanidin A2 som antiatherosclerotiske midler

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees